Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

Exclusion Criteria

• •Taking any medication known to interact with histone deacetylase (HDAC) inhibitors, such as valproate or anticoagulants
• •Taking any medication known to affect hedgehog (HH) signaling pathway such as itraconazole
• •Within the past 6 months, has used topical or systemic therapies that might interfere with the evaluation of the study medication during the study; specifically, these include the topical use to the study tumors of:
• •* Glucocorticoids
• •* Retinoids either systemically or topically (eg, etretinate, isotretinoin, tazarotene, tretinoin, adapalene)
• •* Alpha hydroxy acids (eg, glycolic acid, lactic acid) to \> 5% of the skin
• •* 5 fluorouracil or imiquimod and/or
• •* Itraconazole
• •Has received treatment with systemic chemotherapy or agents known to be inhibitors of HH signaling, within 60 days to starting study medication
• •Currently receiving systemic medications that could affect BCC tumors (eg, oral retinoids) or might interact with remetinostat
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, recurrent seizure history or psychiatric illness/social situations that would limit compliance with study requirements
• •Moderate to severe immunosuppression due to disease or medication
• •Known or previous hypersensitivity to histone deacetylase inhibitor (HDACi)
• •History of congestive heart failure; cardiac arrhythmias; or other findings of ventricular dysfunction
• •History of current evidence of malabsorption or liver disease
• •Pregnancy or breast feeding